Harvard Bioscience, Inc. Schedules Fourth Quarter 2012 Conference Call for February 28, 2013

Harvard Bioscience, Inc. Schedules Fourth Quarter 2012 Conference Call for
February 28, 2013

HOLLISTON, Mass., Feb. 25, 2013 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc.
(Nasdaq:HBIO), a global developer, manufacturer and marketer of a broad range
of specialized products used to advance life science research and regenerative
medicine, will announce results for its fourth quarter and year ended December
31, 2012 before market trading hours on Thursday, February 28, 2013.

A conference call to discuss the company's fourth quarter and year ended
December 31, 2012 financial results is scheduled for Thursday, February 28,
2013 at 11:00 a.m. Boston time. In addition, management may answer questions
concerning business and financial developments and trends, the Company's view
on earnings forecasts, update on its regenerative medicine device business,
and other business and financial matters affecting the Company. Some of the
information to be presented on the call or provided in response to questions
may contain information that has not previously been disclosed.

The conference call will be simultaneously broadcast over the Internet and can
be accessed through the Harvard Bioscience, Inc. website. To listen to the
conference call, log on to our website at www.harvardbioscience.com and click
on the Earnings Call icon. Financial and other statistical information
presented on the call, including our earnings release, will also be available
on the investor relations section of our website. Click on the investor
relations button and then click on the press release or webcast icon, as
appropriate. If you are unable to listen to the live webcast, the call will be
archived in the investor relations section of our website. The live conference
call is also accessible by dialing toll-free 877-303-7611, or toll
970-315-0445, and referencing the pass code of "94630589".

Date: February 28, 2013

Time: 11:00 AM ET

Listen via Internet: http://www.harvardbioscience.com/

Schedule this webcast into MS-Outlook calendar (click open when prompted):
http://apps.shareholder.com/PNWOutlook/t.aspx?m=57519&k=6F75BD6F

A replay of this conference call will be available from approximately 2:00
p.m. on February 28, 2013 through March 7, 2013 and will be accessible by
dialing toll-free 855-859-2056, or toll 404-537-3406, and referencing the pass
code of "94630589".

Harvard Bioscience ("HBIO") is a global developer, manufacturer and marketer
of a broad range of specialized products, primarily apparatus and scientific
instruments, used to advance life science research and regenerative medicine.
HBIO sells its products to thousands of researchers in over 100 countries
primarily through its 850 page catalog (and various other specialty catalogs),
its website, through distributors, including GE Healthcare, Thermo Fisher
Scientific and VWR, and via its field sales organization. HBIO has sales and
manufacturing operations in the United States, the United Kingdom, Germany,
Sweden and Spain with additional facilities in France and Canada. For more
information, please visit www.harvardbioscience.com.

The Harvard Bioscience, Inc. logo is available at
http://www.globenewswire.com/newsroom/prs/?pkgid=8160

The statements made in this press release that are not statements of
historical fact are forward-looking statements within the meaning of Section
27A of the Securities Act of 1933 and Section 21E of the Securities Exchange
Act of 1934. These statements involve known and unknown risks, uncertainties
and other factors that may cause the Company's actual results, performance or
achievements to be materially different from any future results, performance
or achievements expressed or implied by the forward-looking statements.
Factors that may cause the Company's actual results, performance or
achievements to differ materially from those in the forward-looking statements
include, but are not limited to, those factors set forth under the heading
"Item 1A. Risk Factors" in the Company's Annual Report on Form 10-K for the
fiscal year ended December 31, 2011 or described in the Company's other public
filings. The Company's results may also be affected by factors of which the
Company is not currently aware. The Company may not update these
forward-looking statements, even though its situation may change in the
future, unless it has obligations under the federal securities laws to update
and disclose material developments related to previously disclosed
information.

CONTACT: Harvard Bioscience, Inc.

         David Green, President
         dgreen@harvardbioscience.com

         Chane Graziano, CEO
         cgraziano@harvardbioscience.com

         Tom McNaughton, CFO
         tmcnaughton@harvardbioscience.com

         508 893 8999
         Fax: 508 429 8478

Harvard Bioscience, Inc. Logo